

IN THE CLAIMS

Claims 1 (Currently Amended): A method for treating at least one inflammatory pathological skin condition in a subject in need thereof, comprising administering a composition comprising ~~The use of a composition essentially consisting of~~ at least one soluble form of HLA-G and ~~of~~ at least one pharmaceutically acceptable vehicle to the subject in an amount sufficient to treat the at least one inflammatory pathological skin condition, ~~for preparing a medicinal product for treating inflammatory pathological skin conditions.~~

Claim 2 (Currently Amended): ~~The use as claimed in~~ method of claim 1, ~~characterized in that said~~ wherein the at least one soluble form of HLA-G is selected from the group consisting of ~~the~~ soluble isoforms of HLA-G comprising at least the $\alpha 1$ extracellular domain, ~~and the~~ a solubilized ~~from~~ form of HLA-G1, a solubilized form of HLA-G2, a solubilized form of HLA-G3, or a solubilized form of HLA-G4, and a solubilized form of HLA-G5.

Claim 3 (Currently Amended): ~~The~~ method of claim 1 ~~use as claimed in claim 1 or claim 2, characterized in that said~~ wherein the composition comprises between 0.1 and 5 $\mu\text{g/ml}$, ~~preferably between 0.5 and 2.5 $\mu\text{g/ml}$, of the at least one~~ soluble form of HLA-G.

Claim 4 (Currently Amended): A method for preparing a soluble HLA-G,
~~characterized in that it comprises the following steps~~ comprising:

-coinfecting insect cells with a baculovirus ~~containing~~ comprising

the β_2 M cDNA and

another baculovirus ~~containing~~ comprising

the α chain of a soluble isoform of HLA-G;

-culturing the transfected insect cells; ~~and~~

-harvesting the supernatants; and

-purifying the soluble isoform of HLA-G expressed.

Claim 5 (Currently Amended): The method ~~as claimed in~~ of claim 4,
~~characterized in that said~~ wherein the purifying the soluble isoform of HLA-G
expressed comprises ~~soluble isoform of HLA-G is purified using~~ purifying the soluble
isoform of HLA-G with an at least one antibody specific for ~~the~~ at least one soluble
~~isoforms~~ isoform of HLA-G.

Claim 6 (Currently Amended): The method ~~as claimed in~~ of claim 5,
~~characterized in that said~~ wherein the at least one antibody is obtained by immunizing
at least one nonhuman mammal ~~mammals, in particular rabbits,~~ with an
immunogenic peptide of SEQ ID NO: 1 coupled to ~~the~~ a KLH carrier protein.

Claim 7 (Currently Amended): A soluble anti-HLA-G antibody, characterized in that it is obtained by immunizing at least one nonhuman mammal ~~mammals, in particular rabbits,~~ with an immunogenic peptide ~~consisting of~~ comprising a 21 amino acid synthetic peptide of SEQ ID NO: 1 coupled to the KLH carrier protein.

Claim 8 (New): The method of claim 1, wherein the composition comprises between 0.5 and 2.5 $\mu\text{g/ml}$ of the at least one soluble form of HLA-G.

Claim 9 (New): The method of claim 6, wherein the at least one nonhuman mammal is a rabbit.

Claim 10 (New): The soluble anti-HLA-G antibody of claim 7, wherein the at least one nonhuman mammal is a rabbit.